We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Transatlantic Partners to Collaborate on Ready-to-Use Products for Microbiological Diagnostics

By LabMedica International staff writers
Posted on 28 Oct 2013
A recently announced transatlantic partnership is dedicated to developing, manufacturing, and marketing ready-to-use media products for microbiological diagnostics and research applications.

The French/German company Sartorius Stedim Biotech (Aubagne, France) - a leading provider of equipment and services for development, quality assurance, and production in the biopharmaceutical industry - and BD Diagnostics (Franklin Lakes, NJ, USA), a leading global medical technology company, recently announced the formation of a collaborative effort to develop, manufacture, and market various ready-to-use, prefilled media products for detection and diagnosis of microorganisms in clinical and research laboratories. More...


Sartorius Stedim Biotech manufactures high quality, single-use filter products for concentration of microbial contaminants, and as part of this partnership agreement, BD Diagnostics will fill special Sartorius single-use products with BD's culture media and supply these back to Sartorius as prepackaged products.

In addition, the companies will be exploring options for extending their existing business relationship by pursuing further innovative solutions in the field of microbiological diagnostics.

“Through our agreement with BD, we have created an excellent collaboration. BD is known worldwide for its expertise in manufacturing and filling of microbial media. BD’s expertise combined with Sartorius Stedim Biotech’s know-how in polymeric technologies and applications will help us further extend our expert capabilities in the field of microbiological monitoring,” said Dominique Baly, member of the Sartorius group executive committee.

“The products we plan to develop under our agreement with Sartorius Stedim Biotech will enhance laboratory efficiencies for our pharmaceutical, biotech, and research customers with these unique product offerings,” said Bob Ferguson, vice president and general manager of BD Diagnostics. “By combining Sartorius Stedim Biotech’s bioprocessing and filtration expertise with BD’s microbiological media capabilities, customers will benefit from improved lab productivity and standardization of sample processing.”

Related Links:
Sartorius Stedim Biotech
BD Diagnostics 



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.